In a study, the CRISPR-Cas9 knockdown of NANOS3 in glioblastoma cell lines resulted in reduced proliferation, migration, and invasiveness, suggesting a role for NANOS3 in this disease. This evidence concerns the gene NANOS3 and glioblastoma.